Kidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 33305, Taiwan.
College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan.
Nutrients. 2022 Sep 28;14(19):4020. doi: 10.3390/nu14194020.
Background: Rigid dietary controls and pill burden make a very-low protein (0.3−0.4 g/kg body weight per day), vegetarian diet supplemented with ketoanalogues of amino acids (sVLPD) hard to follow in the long-term. This study aimed to evaluate whether a ketoanalogue supplemental low-protein diet (sLPD) (0.6 g/kg body weight per day) could also reduce the risks of dialysis among CKD stage 4 patients. Methods: Patients aged >20 years with a diagnosis of stage 4 CKD who subsequently received ketosteril treatment, which is the most commonly used ketoanalogue of essential amino acids, between 2003 and 2018 were identified from the Chang Gung Research Database (CGRD). Then, these individuals were divided into two groups according to the continuation of ketosteril for more than three months or not. The primary outcome was ESKD requiring maintenance dialysis. Results: With one-year follow-up, the continuation group (n = 303) exhibited a significantly lower incidence of new-onset end-stage kidney disease (ESKD) requiring maintenance dialysis (6.8% vs. 10.4%, hazard ratio [HR]: 0.62, 95% confidence interval [CI]: 0.41−0.94) in comparison to the discontinuation group (n = 238). Conclusions: This study demonstrated that initiating sLPDs since CKD stage 4 may additionally reduce the short-term risks of commencing dialysis without increasing CV events, infections, or mortality.
严格的饮食控制和药物负担使得极低蛋白(每天 0.3-0.4g/kg 体重)、素食饮食补充氨基酸类似物(sVLPD)难以长期遵循。本研究旨在评估补充氨基酸类似物的低蛋白饮食(sLPD)(每天 0.6g/kg 体重)是否也可以降低 4 期 CKD 患者透析的风险。
从长庚研究数据库(CGRD)中确定了 2003 年至 2018 年间接受 ketosteril 治疗的年龄>20 岁且诊断为 4 期 CKD 的患者,ketosteril 是最常用的必需氨基酸类似物。然后,根据 ketosteril 的使用时间是否超过三个月,将这些患者分为两组。主要结局是需要维持性透析的终末期肾病(ESKD)。
在一年的随访中,继续使用 ketosteril 的患者(n=303)新发生需要维持性透析的终末期肾病(ESKD)的发生率明显低于停药组(n=238)(6.8% vs. 10.4%,风险比 [HR]:0.62,95%置信区间 [CI]:0.41-0.94)。
本研究表明,从 CKD 4 期开始使用 sLPD 可能会降低短期开始透析的风险,而不会增加心血管事件、感染或死亡率。